FDA approves OCREVUS ZUNOVO™ as the first and only twice-a-year 10-minute ... - BioSpace

September 16, 2024

FDA approves OCREVUS ZUNOVO™, a twice-a-year subcutaneous injection for relapsing and primary progressive multiple sclerosis, offering more treatment options and flexibility.

Related Clinical Trials

A Phase III, Non-Inferiority, Randomized, Open-Label, Parallel Group, Multicenter Study To Investigate The Pharmacokinetics, Pharmacodynamics, Safety And Radiological And Clinical Effects Of Subcutaneous Ocrelizumab Versus Intravenous Ocrelizumab In Patients With Multiple Sclerosis

Reference News

biospace.com

FDA approves OCREVUS ZUNOVO™ as the first and only twice-a-year 10-minute ... - BioSpace

FDA approves OCREVUS ZUNOVO™, a twice-a-year subcutaneous injection for relapsing and primary progressive multiple sclerosis, offering more treatment options and flexibility.